Anterior and posterior images
View main image(bs) in a separate image viewer
View second image(bs). Spot images
View third image(bs). Current scan at left (ant/post) and prior scan at right (ant/post)
View fourth image(mb). MIBG Scintigraphy
Full history/Diagnosis is available below
Bone scintigraphy early 2004 demonstrated normal bone scintigraphy.
I-123 metaiodobenzylguanidine (MIBG) within a week of the second bone scan demonstrated extensive bone and bone marrow uptake involving nearly the entire skeleton most consistent with metastatic disease.
a. Both MIBG and MDP are useful for the detection of skeletal neuroblastoma. MIBG is the better agent for characterizing the extent of disease, and MDP is a valuable adjunctive agent that provides skeletal landmarks for comparison. MIBG is clearly superior for the detection of extraskeletal neuroblastoma.
b. Some studies (1,3) suggest that MIBG alone may fail to visualize skeletal involvement of neuroblastoma and should therefore be complemented by additional 99mTc-MDP scintigraphy. Therefore, Tc-99m-MDP bone scan should remain a part of routine assessment of patients with neuroblastoma. Studies show that underassessment of skeletal involvement by neuroblastoma occurred using 123I-MIBG scans and that one cannot therefore substitute 123I-MIBG for 99mTc-MDP bone scans in the staging of neuroblastoma.
I-131 MIBG proved especially useful in detecting neuroblastoma with negative Tc-99m MDP and also proved to be helpful with those cases in which I-131 MIBG was planned for therapy.
c. One study (5) found that MIBG imaging did not change the staging or alter treatment during therapy for any patient. However, other studies have found it valuable in staging and monitoring disease.
1. Barai S, Bandopadhayaya GP, Malhotra A, et al. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma? JPGM 2004; 50: 257-261
2. Sohara Y, Shimada H, Scadeng M, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res 2003; 63:3026-31.
3.Bhogate BM, Samuel AM, Ramanathan P. Bone scans in neuroblastoma. Indian J Cancer 1993; 30:5-9.
4. Sautter-Bihl ML, Bihl H, Heinze HG. The place of 99mTc-MDP skeletal scintigraphy in neuroblastoma. Is a new assessment necessary? Nuklearmedizin 1991; 30:7-12.
5. Andrich MP, Shalaby-Rana E, Movassaghi N, Majd M. The role of 131 iodine-metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics 1996; 97:246-50.5.
6. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992; 33:1735-40.
7. Garty I, Friedman A, Sandler MP, Kedar A. Neuroblastoma: imaging evaluation by sequential Tc-99m MDP, I-131 MIBG, and Ga-67 citrate studies. Clin Nucl Med 1989; 14:515-22.
References and General Discussion of Bone Scintigraphy (Anatomic field:Skeletal System, Category:Neoplasm, Neoplastic-like condition)
Return to the Teaching File home page.